Mechanism of Action:
- Dual agonist with improved pharmacokinetics and increased affinity for GLP-1 and glucagon receptors
- Stimulates glucose-dependent insulin secretion
- Suppresses appetite through effects on satiety centers in hypothalamus
- Increases energy expenditure through brown adipose tissue activation
- Improves insulin sensitivity in peripheral tissues
Recommended for:
- Patients with morbid obesity (BMI > 35)
- Type 2 diabetes patients with inadequate control on maximum doses of other drugs
- Individuals with metabolic syndrome and severe insulin resistance
- Ineffectiveness of GLP-1 agonist therapy
Research and Studies:
Phase 2 and 3 clinical studies demonstrate:
- 18-22% weight loss over 36 weeks of therapy
- 2.0-2.5% reduction in HbA1c levels in diabetic patients
- Improvement in cardiometabolic parameters and liver function
- Reduction in cardiovascular event risk
- Efficacy in patients with non-alcoholic fatty liver disease
- Morbid obesity (BMI ≥ 35 kg/m²)
- Type 2 diabetes with inadequate glycemic control
- Metabolic syndrome with severe disorders
- Complex therapy of non-alcoholic fatty liver disease
- Treatment-resistant forms of obesity
The drug is dissolved in appropriate volume of sterile water for injections and administered subcutaneously in the abdominal area. Treatment starts with dose of 5 mg once weekly, with gradual dose increase of 2.5-5 mg every 4 weeks until target dose of 15-20 mg per week is reached. Injections are recommended to be done on the same day of the week.
Contraindications:
- Type 1 diabetes mellitus
- Family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
- History of acute pancreatitis
- Severe renal insufficiency (GFR < 30 ml/min)
Side Effects:
- Nausea, vomiting, diarrhea during dose titration
- Decreased appetite and constipation
- Headache and fatigue
- Injection site reactions
- Increased risk of hypoglycemia in combination with insulin
